# New Multiple Myeloma trials, last 30 days: 20 (2026)

Updated November 19, 2026.

20 new trials for Multiple Myeloma were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New Multiple Myeloma clinical trials, last 30 days: 20 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/new/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 19
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933432 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933432) |
| November 12, 2026 | NCT07932301 | Pre-Transplant Nutrition Counseling in Patients With Multiple Myeloma | University of Utah | Not applicable | Not yet recruiting | Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932301) |
| November 12, 2026 | NCT07931391 | SKCD in Early Relapsed/Refractory Multiple Myeloma | Beijing Chao Yang Hospital | Phase 2 | Recruiting | Multiple Myeloma (MM) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931391) |
| November 10, 2026 | NCT07927842 | BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927842) |
| November 9, 2026 | NCT07927023 | A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | Pfizer | Observational | Not yet recruiting | Multiple Myeloma | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927023) |
| November 3, 2026 | NCT07914556 | Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | AML, Multiple Myeloma, CMML | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914556) |
| November 3, 2026 | NCT07912684 | The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized... | Gruppo Italiano Malattie EMatologiche dell'Adulto | Not applicable | Recruiting | Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912684) |
| November 3, 2026 | NCT07911748 | A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma. | Beijing Mabworks Biotech Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911748) |
| November 2, 2026 | NCT07910903 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910903) |
| October 30, 2026 | NCT07907211 | Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | Sponsor not shown (see the record) | Phase 4 | Recruiting | Multiple Myeloma, Venous Thromboembolism (VTE) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907211) |
| October 30, 2026 | NCT07906418 | BCMA Polymorphisms in Patients With Multiple Myeloma | Başakşehir Çam & Sakura City Hospital | Observational | Not yet recruiting | Multiple Myeloma | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906418) |
| October 29, 2026 | NCT07903636 | QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903636) |
| October 29, 2026 | NCT07903506 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903506) |
| October 29, 2026 | NCT07903272 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants... | Janssen Research & Development, LLC | Phase 3 | Not yet recruiting | Multiple Myeloma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903272) |
| October 28, 2026 | NCT07901868 | Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | PETHEMA Foundation | Phase 2 | Not yet recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901868) |
| October 26, 2026 | NCT07895017 | Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias | University of Virginia | Phase 2 | Not yet recruiting | Thrombocytopenia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895017) |
| October 23, 2026 | NCT07891871 | RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab | The Royal Wolverhampton Hospitals NHS Trust | Observational | Not yet recruiting | Myeloma Multiple | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891871) |
| October 22, 2026 | NCT07887984 | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma | Alliance for Clinical Trials in Oncology | Phase 2/3 | Not yet recruiting | Multiple Myeloma (MM) | 920 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887984) |
| October 21, 2026 | NCT07887672 | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887672) |
| October 20, 2026 | NCT07882069 | Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia | Selcuk University | Not applicable | Completed | Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent, Resilience... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882069) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 3 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| [Kite, A Gilead Company](https://specstream.ai/data/clinical-trials/company/kite-a-gilead-company) | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| University of Utah | 1 |
| Beijing Chao Yang Hospital | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Mabwell (Shanghai) Bioscience Co., Ltd.](https://specstream.ai/data/clinical-trials/company/mabwell-shanghai-bioscience-co-ltd) | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| Beijing Mabworks Biotech Co., Ltd. | 1 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 1 |
| Başakşehir Çam & Sakura City Hospital | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| PETHEMA Foundation | 1 |
| University of Virginia | 1 |
| The Royal Wolverhampton Hospitals NHS Trust | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Selcuk University | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
- [Refinishing companies in the United States](https://specstream.ai/data/businesses/refinishing-companies/united-states)
- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
